Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, has received approval from the National Medical Products Administration for the registration of Famotidine Injection, indicating a significant advancement in the company's product pipeline and potential market expansion [1] Group 1: Product Approval - The approved drug, Famotidine Injection, is a chemical medication developed independently by the group [1] - The indication for the drug is for the treatment of upper gastrointestinal bleeding caused by peptic ulcers, excluding those due to tumors and esophageal or gastric varices [1] Group 2: Research and Development Investment - As of August 2025, the group has invested approximately RMB 7.67 million (unaudited) in the research and development of this drug [1]

Core Points - Recently, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that its subsidiary, Jinzhou Aohong Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the drug registration application of Famotidine injection [1] Group 1 - The approval of Famotidine injection marks a significant milestone for the company in expanding its pharmaceutical product offerings [1]

Group 1 - Yihau New Materials plans to reduce its shareholding by up to 1% of the company's total shares, amounting to 165,500 shares, due to personal funding needs [1] - Fuxing Pharmaceutical's subsidiary has received approval for a new indication for its drug, which is used in the treatment of certain types of breast cancer [1][2] - Shantui Co. has submitted its H-share issuance application to the China Securities Regulatory Commission, which has been accepted [3] Group 2 - Sierte's chairman plans to increase his shareholding by an amount between 3 million to 6 million yuan [4] - Borui Pharmaceutical's BGM0504 tablet has received approval for clinical trials in overweight and obese adults [5] - Ganyue Expressway reported vehicle toll service revenue of 349 million yuan for August [6] Group 3 - Chip Microelectronics has submitted its H-share issuance application to the China Securities Regulatory Commission, which has been accepted [7] - Lingrui Pharmaceutical's director plans to reduce his shareholding by up to 200,000 shares, representing 0.0353% of the total shares [8] - Jiahu Energy has adjusted its share repurchase price limit to 11.63 yuan per share [10] Group 4 - Spring Airlines reported a year-on-year increase of 12.23% in passenger turnover for August [11] - Kaida has received an invention patent for a self-calibrating sensor technology [12] - Chuanheng Co. has obtained a new utility model patent aimed at improving industrial waste utilization [14] Group 5 - Huashi Technology received a government subsidy of 2.21 million yuan, accounting for 22.71% of its latest audited net profit [15] - Shanghai Pharmaceuticals' controlling shareholder plans to increase its H-share holdings by up to 74 million shares [16] - Hongrun Construction has won a bid for a significant segment of the Shanghai Metro Line 21 project, valued at 126 million yuan [18] Group 6 - Sanfangxiang plans to invest 100 million yuan to establish a wholly-owned subsidiary focused on green technology [19] - Lao Fengxiang's subsidiaries plan to jointly invest in luxury goods sales and gold refining companies [20][21] - China Eastern Airlines reported an 8.72% year-on-year increase in passenger turnover for August [22] Group 7 - Inner Mongolia First Machinery has signed a railway freight car procurement contract worth 186 million yuan [22] - Jiuqiang Bio has received five invention patents related to diagnostic reagents [24] - Longmag Technology plans to invest 210 million yuan in its second phase project in Vietnam [25] Group 8 - Galaxy Magnetics plans to acquire 100% equity of Kyoto Longtai, with its stock suspended for trading [26] - Jinlong Co.'s controlling shareholder will have 30 million shares auctioned [27] - Haishi Co.'s controlling shareholder has released the pledge on 29.97 million shares [28] Group 9 - Qiu Tianwei plans to reduce its shareholding by up to 1.17% of the total shares [29] - Xiaocheng Technology's directors plan to reduce their shareholding by a total of 0.08% [30] - Victory Co. reported that Sunshine Life Insurance has reduced its shareholding by 4.4 million shares [31] Group 10 - Xindong Technology plans to distribute a cash dividend of 0.156 yuan per share [32] - Huaqin Technology plans to distribute a cash dividend of 0.13 yuan per share [33] - Kexing Pharmaceutical's controlling shareholder intends to transfer 5% of the company's shares [35] Group 11 - Guojin Securities has completed the repayment of its second short-term financing bond for 1.0205 billion yuan [38] - Chunhui Intelligent Control's application for asset acquisition has been accepted by the Shenzhen Stock Exchange [39] - Chaohongji has submitted its H-share issuance application to the Hong Kong Stock Exchange [40] Group 12 - Tianyue Advanced has fully exercised its over-allotment option, involving 716,180 H-shares [40] - Chengfeng Technology's vice president has resigned due to internal adjustments [41] - Yingpais plans to establish a 100 million yuan technology sports industry investment fund [43]

Core Viewpoint - Shanghai Fosun Pharmaceutical's subsidiary, Jinzhou Aohong Pharmaceutical, has received approval from the National Medical Products Administration for the registration of Famotidine injection, indicating a significant advancement in the company's product pipeline and potential market expansion [1] Group 1: Product Approval - The approved drug, Famotidine injection, is a self-developed chemical medication by the group [1] - The indication for the drug is for treating upper gastrointestinal bleeding caused by peptic ulcers, excluding those due to tumors and esophageal or gastric varices [1] Group 2: Research and Development Investment - As of August 2025, the group has invested approximately RMB 7.67 million (unaudited) in the research and development of this drug [1]

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, has received approval from the National Medical Products Administration for the registration of Famotidine Injection, which is developed in-house and targets upper gastrointestinal bleeding caused by various factors excluding tumors and esophageal or gastric variceal bleeding [1][2]. Group 1: Product Approval - The approval of Famotidine Injection enhances the company's product portfolio [1]. - The drug is specifically indicated for upper gastrointestinal bleeding due to peptic ulcers and other causes [1]. Group 2: Financial Investment and Market Potential - The company has invested approximately RMB 7.67 million in the research and development of this drug as of August 2025 [2]. - The projected sales revenue for Famotidine Injection in mainland China (excluding Hong Kong, Macau, and Taiwan) is estimated to be around RMB 1.377 billion in 2024 [2].

该药品本次获批上市，将进一步丰富本集团产品线。 复星医药（600196）(02196)发布公告，近日，该公司控股子公司锦州奥鸿药业有限责任公司就法莫替 丁注射液(以下简称"该药品")的药品注册申请获国家药品监督管理局批准。 该药品为本集团(即本公司及控股子公司/单位，下同)自主研发的化学药品,本次获批适应症为用于消化 性溃疡所致上消化道出血，除肿瘤及食道、胃底静脉曲张以外的各种原因所致的胃及十二指肠粘膜糜烂 出血者。 截至2025年8月，本集团现阶段针对该药品累计研发投入约为人民币767万元(未经审计)。 根据IQVIA CHPA最新数据，2024年，法莫替丁注射剂于中国境内(不包括港澳台地区)的销售额约为人 民币13.77亿元。 ...

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, received approval from the National Medical Products Administration for new indications of two drugs, indicating a positive development in the company's product pipeline and potential market expansion [1] Group 1: Drug Approvals - The drug citric acid vorinostat capsules (brand name: Fuzhuoning) received approval for a new indication to be used in combination with aromatase inhibitors as initial endocrine therapy for adult patients with hormone receptor-positive and HER2-negative locally advanced or metastatic breast cancer [1] - The drug famotidine injection also received approval for its indication to treat upper gastrointestinal bleeding caused by peptic ulcers and other non-tumor-related conditions, excluding esophageal and gastric variceal bleeding [1]

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the registration of Famotidine Injection, indicating a significant advancement in the company's product portfolio and potential market opportunities [1]. Company Summary - The approved drug, Famotidine Injection, is a chemical medication independently developed by the group [1]. - The approved indication for the drug is for the treatment of upper gastrointestinal bleeding caused by peptic ulcers, excluding those due to tumors and esophageal or gastric varices [1]. Industry Summary - The approval of Famotidine Injection highlights the ongoing innovation and development within the pharmaceutical industry, particularly in the area of gastrointestinal treatments [1].

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, has received approval from the National Medical Products Administration for the registration of Famotidine Injection, indicating a significant advancement in the company's product portfolio and potential market opportunities [1] Group 1: Product Approval - The drug, Famotidine Injection, is a self-developed chemical medication by the group [1] - The approved indication is for the treatment of upper gastrointestinal bleeding caused by peptic ulcers, excluding those due to tumors and esophageal or gastric varices [1] - The approval highlights the company's commitment to addressing various causes of gastric and duodenal mucosal erosion and bleeding [1]

Group 1 - The core point of the article is that Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the drug registration application of Famotidine Injection [1] - The approved indication for the drug is for the treatment of upper gastrointestinal bleeding caused by peptic ulcers, excluding those due to tumors and esophageal or gastric varices [1] - The drug is a chemically synthesized product developed independently by the company and its subsidiaries [1]